CDTX - シダラ・セラピュ―ティクス （Cidara Therapeutics Inc.）

Cidara will more likely than not have success on the launch of their first drug and a mid-stage trial of their second candidate. Click here to read more.

Futures Rise As Luxury Blowout Lifts European Markets; Dollar, Yields Higher US equity futures advanced to end the week as traders remained fixated on the path of monetary policy while assessing stronger than expected corporate earnings as the season nears its end. Contracts on the S&P 500 rose 0.3% at 8:00 a.m. ET while those on the Nasdaq 100 advanced 0.2%. Swiss luxury-goods maker Richemont soared 7.8% to a record on "spectacular sales growth", fueling a broad rally across European luxury stocks. Risk-on sentiment pushed Treasury yields higher. The Bloomberg dollar index was poised for its biggest weekly gain since March while oil prices declined again, set for their fourth weekly loss. Meanwhile, gold is also on course to end the week lower. Iron ore futures are falling sharply for a second day, but still on track for a weekly gain. In premarket trading, Tesla rose 2% after the electric-car maker raised prices of its Model X and Model S cars in the US, the third change in less than a month, while Musk announced that Twitter would have a new CEO in 6 weeks.

Cidara Therapeutics (NASDAQ: CDTX ) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:37 PM. Here''s what investors need to know about the announcement. Earnings Cidara Therapeutics missed estimated earnings by 25.0%, reporting an EPS of $0.03 versus an … Full story available on Benzinga.com

Cidara Therapeutics press release (CDTX): Q1 GAAP EPS of $0.03 beats by $0.07.Revenue of $25.99M (+265.5% Y/Y) beats by $7.31M.

SAN DIEGO (AP) — SAN DIEGO (AP) — Cidara Therapeutics Inc. (CDTX) on Thursday reported first-quarter net income of $2.5…

The Dow Jones closed higher by around 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. Cidara Therapeutics The Trade: Cidara Therapeutics, Inc. (NASDAQ: CDTX ) President and CEO Jeffrey Stein acquired a total 50,000 shares an average price of $1.04. To acquire these shares, it cost around … Full story available on Benzinga.com

Cidara Therapeutics (NASDAQ: CDTX ) brought in sales totaling $10.22 million during Q4 according to data provided by Benzinga Pro . However, earnings decreased 189.31%, resulting in a loss of $13.38 million. In Q3, Cidara Therapeutics earned $14.98 million, and total sales reached $40.74 million. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com

Dermata Therapeutics (DRMA) +40%. GH Research (GHRS) +27%. Cidara Therapeutics (CDTX) -9%. BridgeBio Pharma (BBIO) -9%. Read more here

The FDA approved Cidara Therapeutics Inc''s (NASDAQ: CDTX ) antifungal Rezzayo (rezafungin) under priority review for treating candidemia and invasive candidiasis in adults with limited or no alternative treatment options, the company announced Wednesday. While the EMA accepted the marketing authorization application for rezafungin in August 2022, it is still under review for potential approval in Europe. Last year, Melinta Therapeutics acquired the rights to commercialize Rezzayo in the … Full story available on Benzinga.com

ZyVersa Therapeutics (ZVSA) +33%. Aziyo Biologics (AZYO) +29%. Cidara Therapeutics (CDTX) -20%. Protagenic Therapeutics (PTIX) -19%.

In last trading session, Cidara Therapeutics Inc. (NASDAQ:CDTX) saw 0.42 million shares changing hands with its beta currently measuring 1.53. Company’s recent per share price level of $0.63 trading at $0.0 or 0.79% at ring of the bell on the day assigns it a market valuation of $45.08M. That closing price of CDTX’s stock is … Cidara Therapeutics Inc. (NASDAQ:CDTX) Is 36.51% Above Its 52-Week Low, But How Long Will It Remain So? Read More »

Cidara Therapeutics press release (NASDAQ:CDTX): Q2 GAAP EPS of -$0.19 beats by $0.09.Revenue of $6.22M (-81.1% Y/Y) beats by $0.01M.

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its corporate activities and product pipeline.

On Thursday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX ) experienced volatile short activity. After the activity, the stock price went down -3.74% to $0.72. The overall sentiment for CDTX has been Bearish. The signal from the volatility alert is trending Bearish . Therefore, the recommendation is to Increase Short Exposure. The volatility alert was produced on the prior trading date, 8/4/2022 with a volatility change of +85.10%. The current volatility indicator stands at 11.217. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves … Full story available on Benzinga.com

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Mind-boggling stocks: Helbiz, Inc. (NASDAQ:HLBZ 4.67%), Cidara Therapeutics, Inc. (NASDAQ:CDTX -5.25%) appeared first on Stocks Equity .